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The impact of antimicrobial resistance on clinical outcomes is the subject of ongoing investigations, although uncertainty re-
mains about its contribution to mortality. We investigated the impact of carbapenem resistance onmortality in Pseudomonas
aeruginosa bacteremia in a prospective multicenter (10 teaching hospitals) observational study of patients with monomicrobial
bacteremia followed up for 30 days after the onset of bacteremia. The adjusted influence of carbapenem resistance onmortality
was studied by using Cox regression analysis. Of 632 episodes, 487 (77%) were caused by carbapenem-susceptible P. aeruginosa
(CSPA) isolates, and 145 (23%) were caused by carbapenem-resistant P. aeruginosa (CRPA) isolates. The median incidence den-
sity of nosocomial CRPA bacteremia was 2.3 episodes per 100,000 patient-days (95% confidence interval [CI], 1.9 to 2.8). The
regression demonstrated a time-dependent effect of carbapenem resistance onmortality as well as a significant interaction with
the Charlson index: the deleterious effect of carbapenem resistance onmortality decreased with higher Charlson index scores.
The impact of resistance onmortality was statistically significant only from the fifth day after the onset of the bacteremia, reach-
ing its peak values at day 30 (adjusted hazard ratio for a Charlson score of 0 at day 30, 9.9 [95% CI, 3.3 to 29.4]; adjusted hazard
ratio for a Charlson score of 5 at day 30, 2.6 [95% CI, 0.8 to 8]). This study clarifies the relationship between carbapenem resis-
tance and mortality in patients with P. aeruginosa bacteremia. Although resistance was associated with a higher risk of mortal-
ity, the study suggested that this deleterious effect may not be as great during the first days of the bacteremia or in the presence of
comorbidities.
Pseudomonas aeruginosa is a leading cause of nosocomial in-fections, which are often severe (26, 43) and difficult to
treat because of their limited susceptibility to antimicrobial
agents (35) and the frequent emergence of antibiotic-resistant
mutants during therapy (8). Factors related to the host, the
organism, and the treatment may increase mortality. With re-
gard to the host, the severity of the underlying disease may be
synergistic with infection due to resistant organisms; concom-
itantly, increased virulence could explain the adverse impact of
resistant pathogens on clinical outcomes, although this associ-
ation has not been demonstrated to date. In addition, factors
such as decreased antibiotic effectiveness or a delay in the ini-
tiation of therapy may contribute to adverse outcomes in pa-
tients infected by resistant pathogens (17).
The problem of antibiotic-resistant organisms is increasing
(18), and the impact of antimicrobial resistance on clinical out-
comes is the subject of ongoing investigations (2, 5, 9, 15, 25–28,
32, 33, 40, 41, 43), although its contribution to mortality remains
uncertain. Measurements of its impact on patients are, by neces-
sity, derived essentially from observational studies, and therefore,
an adequate control of confounding variables is essential. The
choice of possible confounders is usually based only on the statis-
tical significance of the association between them and the expo-
sure; thus, the classical criteria of confounding, also based on the
relationship with the outcome and the exposure-outcome path-
way, are usually ignored (24).
Carbapenems are commonly used as first-line agents for nos-
ocomial infections, since their spectrum includes P. aeruginosa,
which is high on the list of Gram-negative pathogens frequently
isolated (37). Nevertheless, carbapenem-resistant and multidrug-
resistant P. aeruginosa strains are being increasingly recognized
(18, 39), and several studies have suggested higher mortality rates
among patients infected by nonsusceptible P. aeruginosa strains
(2, 25, 26, 28, 40, 41), although the real effect on mortality in P.
aeruginosa bacteremia is still unknown. Furthermore, a study per-
formed at one of the participating hospitals (40) showed that pa-
tients with carbapenem-resistant P. aeruginosa (CRPA) bacter-
emia had similar attributable mortality but slow initial mortality
compared to patients infected with susceptible strains. This
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knowledge can guide antibiotic policy away from aggressive em-
pirical therapy and the associated adverse events, increased costs,
and increased selective pressure for more antibiotic resistance.
We designed a prospective, multicenter, large-scale, observa-
tional study of patients with P. aeruginosa bacteremia, with the
main objective of investigating the impact of carbapenem resis-
tance on mortality.
MATERIALS AND METHODS
Setting and design. Ten public hospitals located in four areas of Spain
(Andalusia, the Balearics, Cantabria, and Catalonia) participated in the
study between January 2008 and December 2009. All adult patients (18
years old) with bacteremia due to P. aeruginosa were recruited prospec-
tively through daily reviews of blood culture results at the participating
centers. Episodes with polymicrobial bacteremia were excluded. Patients
were monitored for 30 days after the first positive blood culture, and the
registered event was death. Bacteremia occurring more than 14 days after
the first positive blood culture was considered a new episode. The study
was approved by the local ethics committees of the participating centers.
Variables and definitions. The following data were recorded: age and
sex; comorbidities and severity of underlying diseases, calculated by using
the Charlson comorbidity index (10); severity of illness, estimated by the
simplified acute physiology score (SAPS II) for intensive care unit (ICU)
patients (34); presence of neutropenia (absolute granulocyte count of
500 granulocytes/ml) and use of immunosuppressive therapy (chemo-
therapy, radiotherapy, and/or immunosuppressive drugs during bacter-
emia presentation); source of bacteremia (21); severity of acute illness at
presentation according to the Pitt bacteremia score (11); presence of sep-
tic shock or severe sepsis andmultiorgan dysfunction syndrome (MODS)
at presentation and at 48 h (3); and antimicrobial treatment received.
CRPA was defined as isolates with imipenem and/or meropenem
MICs of8 mg/liter (Clinical and Laboratory Standards Institute [CLSI]
intermediate and resistant categories). Bacteremia was defined as being
nosocomially acquired when the infection occurred more than 48 h after
admission to the hospital. Episodes of community-acquired bacteremia
were further classified as being health care associated according to criteria
described previously by Friedman et al. (20). The source of bacteremia
was divided into two categories: low risk, including bacteremias of urinary
tract and vascular catheter origins, and high risk, including all other
sources (27). Empirical antimicrobial therapy was considered adequate
when an antimicrobial regimen that included an active antimicrobial was
administered within 24 h of the extraction of the blood sample and before
susceptibility was known; aminoglycoside monotherapy was considered
an inadequate treatment for P. aeruginosa pneumonia. Definitive antimi-
crobial therapywas considered therapy administered according to suscep-
tibility results. A delay in adequate antimicrobial therapy was defined as
the time from bacteremia until the administration of the empirical or
definitive adequate therapy. Additional therapywas defined as procedures
required to control the source of bacteremia (removal of vascular or uri-
nary catheters as well as surgical or percutaneous drainage of collections).
Microbiological studies. The blood isolates were studied at the
participating centers and sent to a reference laboratory (Servicio de Mi-
crobiología, Hospital Universitario de Bellvitge, Barcelona, Spain). P.
aeruginosa strains were identified and tested for their antimicrobial sus-
ceptibilities by individual laboratories using standard techniques. In the
reference laboratory, the antibiotic susceptibilities of 606 available isolates
were confirmed by the disk diffusionmethod (12). CLSI criteria (13) were
used to define susceptibility or resistance to the following antimicrobials
tested: piperacillin, ticarcillin, piperacillin-tazobactam, ceftazidime,
cefepime, aztreonam, imipenem,meropenem, ciprofloxacin, gentamicin,
tobramycin, amikacin, and colistin. Multiresistance was defined accord-
ing to criteria described elsewhere previously (36).
The production of transferable class B carbapenemases (metallo--
lactamases [MBLs]) was investigated by phenotypic (Etest MBL) and ge-
notypic (PCR and sequencing) testing (23). Additionally, the prevalence
of classical chromosomal (mutational) resistance mechanisms was re-
cently analyzedwith a sample of 190 isolates from this cohort (7). In order
to determine clonal relatedness, chromosomal DNAs from these 190 iso-
lates were processed for analysis by pulsed-field gel electrophoresis
(PFGE) (42).
Statistical analysis. The initially required sample size (560 samples)
was calculated based on the results of a retrospective study (40), in order
to detect a risk ratio (RR) between carbapenem resistance andmortality of
at least 1.4, with  and  probabilities of 5% and 20%, respectively; a
carbapenem-susceptible P. aeruginosa bacteremia (nonexposed group)
mortality rate of 35%; and an expected CRPA/carbapenem-susceptible P.
aeruginosa (CSPA) ratio of 1 to 3. The analysis performed after having
exceeded the number of patients required showed a smaller difference in
the effect than expected; therefore, the recruitment of patients was
stopped due to logistical difficulties in achieving the recalculated sample
size (1,644 patients).
The nosocomial incidence rate of P. aeruginosa bacteremia was ad-
justed by the number of stays and is expressed as the rate per 100,000
patient-days. Incidence estimations and confidence intervals (CIs) were
calculated with the exact (Poisson)method. As no population census data
were available, population incidence rates were not calculated.
Survival curves were constructed by means of the Kaplan-Meier
method, and the log rank test was used for comparisons between groups.
Cox hazard regression was used to estimate the most unbiased mea-
sure of the effect of resistance (exposure) on the time to mortality (out-
come) (24). The outcome evaluated was death, the patient admission was
the unit of analysis, and the date of collection of the initial P. aeruginosa
isolate was considered to be time zero. Cases were censored on day 30;
those lost to follow-up were censored on the last follow-up day that they
were known to be alive. As the finalmodel did not satisfy the proportional
hazard assumptions, the variables resistance and Pitt index were modeled
as time-dependent variables. Thus, the finalmodel was a nonproportional
hazard model, in which time-dependent variables had different effects
depending on the time point considered (14).
To assess effect modifications, possible interaction terms between the
exposure variable (resistance) and covariates were examined and main-
tained in the model depending on the results of the significance test (P
0.05). To control for confounding, variables were first screened to meet
three classical criteria (38). In the crude analysis, variables that were asso-
ciated (P  0.20) with exposure (resistance), those that were associated
(P 0.20) with the outcome (mortality), and those that were not consid-
ered to be an intermediate variable between resistance andmortality were
candidates for multivariate analysis. Variables and subsets of variables
which led to substantial confounding if removed (10% change or more in
the coefficient estimate) were maintained in the model, together with
exposure (resistance). Results of the final model were expressed as the
adjusted hazard ratio (aHR) for carbapenem resistance given different
values of the interaction variables at different time points. All statistical
tests were two tailed; a P value of 0.05 was considered significant. All
statistical analyses were performed with the SPSS package, version 15.0.
RESULTS
A total of 638 episodes of P. aeruginosa bacteremia from 10 par-
ticipating centers were entered into the study. Six episodes were
excluded: three episodes with patients younger than 18 years of
age, one episode that did not have complete information, one
episode with a blood specimen that was obtained only through a
vascular catheter without signs or symptoms of infection, and one
remaining episode thatwas finally identified as polymicrobial bac-
teremia in the reference laboratory. Therefore, 632 episodes were
available for evaluation, 487 (77%) CSPA and 145 (23%) CRPA
episodes. In addition, nine patients were lost to follow-up: seven
patients with CSPA and two with CRPA bacteremias. Epidemio-
logical and clinical characteristics of the cohort are shown in Table
Peña et al.
1266 aac.asm.org Antimicrobial Agents and Chemotherapy
1. A recurrence of P. aeruginosa bacteremia within 14 days after
the initial episode occurred in 3 episodes of CSPA infection; the 3
pairs of initial and subsequent P. aeruginosa strains isolated from
the same patients were found to be clonally identical and showed
identical susceptibility patterns.
The numbers of P. aeruginosa episodes in each hospital are
shown in Fig. 1. Among the nosocomial episodes, the median
incidence density of P. aeruginosa bacteremia was 7.9 episodes per
100,000 patient-days (95% CI, 7.1 to 8.8), and that of CRPA bac-
teremia was 2.3 episodes per 100,000 patient-days (95% CI, 1.9
to 2.8).
Microbiology results. A total of 23% of the isolates were non-
susceptible to imipenem, 21.5% were nonsusceptible to mero-
penem, and 21% were resistant to both carbapenems. Just under
one-fifth (19.6%) of the isolates met the established criteria for
multiresistance (36); only amikacin (96.9%) and colistin (100%)
showed conserved activity in most of the isolates.
Six of the isolates (1%), from four different hospitals, were
found to produce MBLs (5 VIM-2 isolates and 1 VIM-20 isolate).
In contrast, an analysis of a subset of 190 isolates from the collec-
tion revealed a high prevalence of chromosomal resistance mech-
anisms: up to 39% of the isolates overexpressed the -lactamase
AmpC or one of the major multidrug efflux pumps, and all tested
imipenem-resistant isolates were deficient in the carbapenem
porin OprD (7).
PFGE analysis showed a notable clonal diversity, with up to 152
different genotypes detected among the isolates investigated. Nev-
ertheless, a significant clonal dissemination of multiresistant iso-
lates was also shown: among 35 multiresistant P. aeruginosa iso-
lates studied, one genotype prevailed (20/35 isolates [57%]),
which was found mainly in hospitals in Catalonia (18/20 [90%]).
Patient characteristics according to carbapenemsusceptibil-
ity. The demographic and clinical characteristics of patients with
P. aeruginosa bacteremia according to carbapenem susceptibility
are shown in Table 2. Among the 145 patients with CRPA bac-
teremias, acquisition was mainly nosocomial; they were more fre-
quent in ICU patients (40% versus 23% [P  0.001]), and the
median number of days between hospital admission and the bac-
teremia episode was significantly higher for these patients than for
patients with CSPA infections. Patients in the CSPA group were
more likely than those in the CRPA group to have bacteremia
from a high-risk source (272 [56%] CSPA patients versus 69
[48%] CRPA patients [P 0.08]).
Mortality. The 30-day mortality cumulative incidence rates
TABLE 1 Epidemiological and clinical characteristics of the 632
episodes of P. aeruginosa bacteremia
Variablea n %
Median age (yr) (IQR) 68 (55.5–77.5)
No. of male patients 433 69
Carbapenem resistance 145 23
Type of acquisition
Nosocomial 362 57
Community 33 5
Health care 237 38
ICU admission 145 23
Mean SAPS II (SD) 42.60 (17.9)
Median Charlson index (IQR) 2 (1–4)
Underlying condition 534 85
Solid malignancy 178 28
Diabetes 164 26
Immunosuppression 157 25
Heart disease 115 18
Chronic renal failure 100 16
Hematologic malignancy 93 15
Chronic lung disease 94 15
Neutropenia 67 11
Chronic neurologic disease 43 7
Cirrhosis 34 5
AIDS 7 1
High-risk/low-risk bacteremia 341/291 54/46
Origin of bacteremia
Urinary tract 170 27
Unknown 170 27
Vascular catheter 121 19
Respiratory tract 73 12
Intra-abdominal 64 10
Soft tissue 20 3
Other 14 2
Clinical presentation of:
Pitt score of2 271 43
Initial shock/MODS 160 25
Shock/MODS at 48 h 135 21
Antibiotic therapy
Empirical 582 92
Adequate empirical 396 68
Additional 199 31.5
Outcome
30-day mortality 183 29
48-h mortality 64 10
a IQR, interquartile range.
FIG 1 Episodes of bacteremia due to P. aeruginosa at participating hospitals.
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TABLE 2 Baseline characteristics of patients with carbapenem-susceptible and carbapenem-resistant P. aeruginosa bacteremias
Characteristica
Value for group
RR 95% CI P
CSPA (n 487
[77%])
CRPA (n 145
[23%])
Median age (yr) (IQR) 68.5 (56–79) 67.5 (57–76) 0.48
No. (%) of male patients 322 (66) 111 (77) 1.44 1.05–1.99 0.018
No. (%) with nosocomial/health care acquisition 454 (93) 145 (100) 1.07 1.05–1.1 0.001
Median no. of days from admission until bacteremia (IQR) 16 (7–28) 23.5 (13.5–43) 0.001
No. (%) with ICU stay 112 (23) 58 (40) 1.7 1.3–2.2 0.001
Mean SAPS (SD) 42 (32–54) 39 (25–56) 0.71
Median Charlson index (IQR) 3 (1–4) 0.23
No. (%) with underlying condition
Any 410 (84) 124 (85.5) 1.1 0.7–1.7 0.69
Solid malignancy 14 33 0.76 0.5–1.1 0.10
Diabetes 128 36 0.9 0.7–1.3 0.73
Immunosuppressive therapy 109 48 1.5 1.1–2.0 0.009
Cardiopathy 86 29 1.1 0.8–1.7 0.52
Chronic renal failure 73 27 1.2 0.8–1.9 0.29
Hematologic malignancy 73 20 0.9 0.6–1.5 0.72
Neurologic disease 33 10 1.0 0.5–2.0 0.96
Neutropenia 54 13 0.8 0.5–1.4 0.5
Cirrhosis 22 12 1.8 0.9–3.6 0.08
AIDS 5 2 1.3 0.3–6.9 0.66
No. (%) with origin of bacteremia
High risk 272 (56) 69 (48) 0.9 0.7–1.0 0.08
Urinary tract 126 44 1.2 0.9–1.6 0.29
Vascular catheter 89 32 1.2 0.8–1.7 0.3
Unknown 140 30 0.7 0.5–1.0 0.05
Respiratory tract 52 21 1.4 0.8–2.2 0.21
Abdominal/biliar 52 12 0.8 0.4–1.4 0.4
Soft tissue 16 4 0.8 0.3–2.5 0.75
Other 12 2 0.6 0.2–2.2 0.44
No. (%) with clinical presentation of:
Pitt score of2 200 (41) 71 (49) 1.2 1.0–1.4 0.09
Initial shock/MODS 115 (24) 45 (31) 1.3 1.0–1.8 0.07
Shock/MODS at 48 h 95 (20) 40 (28) 1.4 1.0–1.9 0.04
No. (%) on antimicrobial empirical therapy 445 (91) 137 (94.5) 1.0 1.0–1.1 0.22
No. (%) with type of empirical treatment of:
Carbapenems 94 (19) 52 (36) 1.9 1.4–2.5 0.001
Fluoroquinolones 59 (12) 12 (8) 0.7 0.4–1.2 0.20
Piperacillin-tazobactam 134 (28) 42 (29) 1.1 0.8–1.4 0.73
Antipseudomonal cephalosporins 110 (20.5) 26 (18) 0.9 0.8–1.0 0.23
Aminoglycosides 71 (15) 38 (26) 1.8 1.3–2.5 0.001
Colistin 6 (1) 6 (4) 3.4 1.1–10.3 0.04
No. (%) with adequate empirical therapy 338 (76) 58 (42) 0.6 0.5–0.7 0.001
No. (%) with adequate therapyb 438 (94) 131 (94) 1 1–1 1
No. (%) with delay of adequate treatment of24 h 286 (65) 52 (40) 0.6 0.5–0.8 0.001
No. (%) with additional therapy 142 (29) 57 (39) 1.3 1.1–1.7 0.021
No. (%) with outcome of:
30-day mortality 132 (27) 51 (35) 1.3 1.0–1.7 0.06
48-h mortality 63 (13) 17 (12) 0.9 0.5–1.5 0.70
a IQR, interquartile range.
b Adequate empirical and/or definitive treatment (excluding 24 patients who did not receive either empirical or definitive treatment).
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were 27% for the CSPA group (132 of 487 patients) and 35% for
the CRPA group (51 of 145 patients). Figure 2 shows the 30-day
survival curves and a comparison between the groups (P 0.10).
Although themortality rates were similar for the groups at the end
of the first 72 h (63 [13%] patients in the CSPA group died, versus
17 [12%] in the CRPA group [P  0.7]), the Kaplan-Meier sur-
vival curves (Fig. 2) showed a higher mortality rate for the CSPA
group in the first 2 days than for the CRPA group (12% versus 7%
[the P value was not significant]).
The unadjusted analyses of the association of the cohort
characteristics with mortality are shown in Table 3. The results
of the crude analysis showed that carbapenem resistance did
not have a significant impact onmortality (HR, 1.3; 95%CI, 0.9
to 1.8; P  0.11). An adjusted analysis with Cox regression
controlled for the source of bacteremia (high/low risk), the Pitt
index, and a delay of less than 24 h to receive adequate antimi-
crobial therapy showed a significant interaction between car-
bapenem resistance and the Charlson index (Table 4). At all
time points considered, the highest risk of mortality associated
with carbapenem resistance was observed for the patients with
the lowest Charlson index scores. The risk fell steadily as the
number of comorbidities rose.
Carbapenem resistance significantly increased the risk of mor-
tality from the fifth day after the onset of bacteremia (data not
shown). However, this association was found to be not significant
during the first 4 days, independent of the Charlson value.
DISCUSSION
The incidence of carbapenem resistance in P. aeruginosa strains
has increased in recent years due to the growing resistance of this
organism to antibiotics. This increase has been reported all over
the world, although there are regional differences in rates (39). In
fact, the nosocomial rates of carbapenem resistance in our study
show a strong geographical variation inside Spain. Differences in
antimicrobial consumption or epidemiological features in partic-
ular areasmay contribute to these differences, althoughmolecular
analysis suggests that to some extent, the cross-transmission of
carbapenem-resistant strains in the hospital and even in the inter-
hospital setting may be responsible.
This report is the largest prospective cohort study to include a
detailed clinical investigation of the impact of carbapenem resis-
tance on mortality in patients with P. aeruginosa bacteremia. Our
data show that carbapenem resistance was associated with signif-
icantly increased 30-day mortality rates but that the relationship
depended on the degree of severity of the underlying disease (19,
30). In fact, our study describes an interaction between carba-
penem resistance and underlying conditions, with an impact on
mortality that is significantly higher for less severely ill patients.
In spite of the belief that infections caused by antibiotic-
resistant organisms result in higher mortality rates, the studies
that have evaluated this problem have produced conflicting re-
sults. There are many possible reasons for these discrepancies,
since the data are highly dependent on the methods used (6). The
differences observed may result, in part, from limitations in the
design of retrospective studies (2, 9, 25, 26, 28, 40, 41), usually
performed to identify the predictors ofmortality (2, 25, 26, 28, 40,
41), and an inability to properly control for illness severity and
underlying disease (16). Another potential confounder is the dif-
ferent pathogenic potentials of the causative pathogens under
study (5, 27, 33). In addition, the types of infection, particularly
those with poor prognoses, may differ or may not be balanced
between the groups being compared (6). Finally,many studies had
smaller numbers of patients with P. aeruginosa infection, thereby
decreasing their statistical power.
FIG 2 Kaplan-Meier survival curves of carbapenem-resistant and carbapenem-susceptible P. aeruginosa bacteremias (P 0.10 by log rank test).
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Few studies have quantified the direct impact of antibiotic re-
sistance (9, 31, 32). Carmeli et al. (9) showed previously that re-
sistance to P. aeruginosa was not associated with increased
mortality. In another study (31), despite the increases in the pro-
portion of resistant organisms observed, no significant differences
were found for the relative risk of death due to a resistant pheno-
type of the target pathogen. Finally, a recent cohort study (32)
showed that the additional effect of antimicrobial resistance on
mortality related to health care-associated infections was compar-
atively low.
Patients with a greater severity of underlying disease may have
many reasons for increased mortality, and the addition of bac-
teremia due to antimicrobial resistance to their life-threatening
problems may be inconsequential. Thus, it is essential to select an
adequatemethodology (6, 17, 29) and adjust for the severity of the
illness and comorbidities before infection, as these factors can
have a significant effect on themeasurement of outcomes.We feel
that we used the bestmethodology available to us; certain research
questions can be answered only by use of observational studies,
due to obvious ethical constraints. By using a predetermined uni-
form endpoint of mortality at 30 days, we avoided the potential
bias in the assignment of a cause of death, which is particularly
problematic for patients with many comorbid conditions. Re-
garding the type of infection, microbiologically documented bac-
teremia represents the optimal model for investigating the patho-
genic significance of resistance. Finally, we used a standardized
underlying disease index, the Charlson comorbidity score, a valid
method for estimating the risk of death from comorbid disease,
and we measured comorbidities before the development of bac-
teremia.
Finally, our study suggests that the increase in mortality ex-
plained by carbapenem resistance is not evident during the first
days after the onset of bacteremia, as a recent single-center study
indicated (40). These findings may be consistent with in vitro ev-
TABLE 3 Crude analysis of effects of carbapenem resistance and other variables on mortality
Covariatea
Value for group
HRb 95% CI PCensored Died
Total no. (%) 449 (71) 183 (29)
No. (%) with carbapenem resistance 94 (21) 51 (28) 1.3 0.9–1.8 0.11
Median age (yr) (range) 65.5 (54.5–76.5) 71.5 (60.5–79.5) 1.1 1.0–1.0 0.002
No. (%) of male patients 311 (69) 122 (67) 1.1 0.8–1.5 0.60
No. (%) with nosocomial/health care acquisition 424 (94) 175 (96) 1.1 0.5–2.2 0.80
Median Charlson index (IQR) 2 (1–4) 3 (2–5) 1.1 1.1–1.2 0.001
No. (%) with high-risk bacteremia 207 (46) 134 (73) 2.7 2.0–3.8 0.001
No. (%) with origin of bacteremia
Urinary tract 142 (32) 28 (15) 0.4 0.3–0.7 0.001
Vascular catheter 100 (22) 21 (11) 0.5 0.3–0.8 0.002
Unknown 99 (22) 71 (39) 2.0 1.5–2.7 0.001
Respiratory tract 34 (7.5) 39 (21) 2.5 1.8–3.6 0.001
Abdominal/biliar 54 (12) 10 (5.5) 0.5 0.2–0.9 0.02
Soft tissue 11 (2.5) 9 (5.5) 1.6 0.8–3.1 0.17
Other 9 (2) 5 (3) 1.3 0.5–3.1 0.60
No. (%) with clinical presentation of:
Pitt score of2 139 (30) 132 (72) 4.5 3.3–6.3 0.001
Initial shock/MODS 68 (15) 92 (50) 4.2 3.1–5.6 0.001
Shock/MODS at 48 h 38 (9) 97 (56) 7.7 5.7–10.4 0.001
No. (%) with adequate empirical antimicrobial therapy 290 (70) 106 (64) 0.8 0.6–1.1 0.19
No. (%) with delay of adequate treatment of24 h 241 (57) 97 (67) 1.5 1.1–2.1 0.02
No. (%) with additional therapy 166 (37) 33 (18) 0.4 0.3–0.6 0.001
a IQR, interquartile range.
b HR, hazard ratio.
TABLE 4 Adjusteda effect of carbapenem resistance on mortalityb
Day Charlson index aHRc 95% CI P
2 0 1.7 0.8–3.3 0.16
1 1.5 0.8–3.0 0.24
2 1.1 0.6–1.9 0.83
3 0.8 0.5–1.6 0.67
4 0.6 0.3–1.0 0.55
5 0.6 0.3–1.1 0.09
7 0 2.2 1.2–4.1 0.01
1 2.0 1.1–3.8 0.01
2 1.4 0.9–2.3 0.12
3 1.3 0.8–2.1 0.36
4 0.8 0.5–1.3 0.31
5 0.7 0.4–1.3 0.31
30 0 9.9 3.3–29.4 0.001
1 8.7 2.9–26.2 0.001
2 5.8 2.0–16.4 0.001
3 6.7 1.8–24.3 0.004
4 3.5 1.1–11.0 0.04
5 2.6 0.8–8.0 0.1
a Adjusted by the source of bacteremia (high risk/low risk), the Pitt score, and a delay of
less than 24 h to receive adequate antibiotic therapy.
b Shown is the interaction between carbapenem susceptibility and the Charlson index at
different time points.
c aHR, adjusted hazard ratio.
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idence showing that resistance genes or mutations can alter the
fitness of microorganisms (4), making them less virulent and re-
ducing their capacity to generate deleterious host inflammatory
responses (22). Nevertheless, the complex interplay between re-
sistance mechanisms, cost-compensatory mutations, fitness, and
virulence in the clinical setting has yet to be fully elucidated (1).
The present investigation may have limitations. Unfortu-
nately, because of the lack of statistical power to detect true but
small differences, the inferences that can be made from our data
may be limited despite the large sample size. In addition, a system
to score the severity of acute illness, which is well validated for
predicting bacteremia prognoses (11), was assessed at the time of
bacteremia presentation. If the severity of the illness was an inter-
mediate variable in the causal pathway between carbapenem re-
sistance and mortality, adjustment by that variable could have led
to an underestimation of the magnitude of the effect (16); how-
ever, no such association was demonstrated. In our opinion, this
multi-institutional study reflects a broad spectrum of patients,
and given the fact that we derived our cohort from a multicenter
study, we believe that these results are applicable to other settings.
In conclusion, to our knowledge, this is the first prospective
multicenter study to investigate the adjusted impact of antimicro-
bial resistance on the mortality of P. aeruginosa bloodstream in-
fections. We have documented the distribution of this epidemio-
logical problem in Spain. The hospitals studied showed marked
diversity in the occurrence of these strains, and this heterogeneity
is due, at least in part, to clonal dissemination. The study clarifies
the relationship between carbapenem-resistant P. aeruginosa bac-
teremia and mortality, although the impact was observed mainly
for patients with a lower severity of underlying disease. The lesser
effect of resistance during the first days after the onset of bacter-
emia may have implications for the design of empirical antibiotic
strategies. Better risk scores should be developed to distinguish
patients at a low risk of mortality due to infections with
antimicrobial-resistant pathogens from those for whom the
broadest-spectrum therapy could be truly beneficial.
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